- United States
- /
- Biotech
- /
- NasdaqCM:ACHV
Achieve Life Sciences, Inc. (NASDAQ:ACHV): What Does Its Beta Value Mean For Your Portfolio?
Anyone researching Achieve Life Sciences, Inc. (NASDAQ:ACHV) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory. Investors may think of volatility as falling into two main categories. The first type is company specific volatility. Investors use diversification across uncorrelated stocks to reduce this kind of price volatility across the portfolio. The other type, which cannot be diversified away, is the volatility of the entire market. Every stock in the market is exposed to this volatility, which is linked to the fact that stocks prices are correlated in an efficient market.
Some stocks mimic the volatility of the market quite closely, while others demonstrate muted, exagerrated or uncorrelated price movements. Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). While we should keep in mind that Warren Buffett has cautioned that 'Volatility is far from synonymous with risk', beta is still a useful factor to consider. To make good use of it you must first know that the beta of the overall market is one. A stock with a beta greater than one is more sensitive to broader market movements than a stock with a beta of less than one.
Check out our latest analysis for Achieve Life Sciences
What ACHV's beta value tells investors
Given that it has a beta of 1.19, we can surmise that the Achieve Life Sciences share price has been fairly sensitive to market volatility (over the last 5 years). If this beta value holds true in the future, Achieve Life Sciences shares are likely to rise more than the market when the market is going up, but fall faster when the market is going down. Share price volatility is well worth considering, but most long term investors consider the history of revenue and earnings growth to be more important. Take a look at how Achieve Life Sciences fares in that regard, below.
How does ACHV's size impact its beta?
Achieve Life Sciences is a rather small company. It has a market capitalisation of US$7.5m, which means it is probably under the radar of most investors. Relatively few investors can influence the price of a smaller company, compared to a large company. This could explain the high beta value, in this case.
What this means for you:
Since Achieve Life Sciences has a reasonably high beta, it's worth considering why it is so heavily influenced by broader market sentiment. For example, it might be a high growth stock or have a lot of operating leverage in its business model. In order to fully understand whether ACHV is a good investment for you, we also need to consider important company-specific fundamentals such as Achieve Life Sciences’s financial health and performance track record. I highly recommend you dive deeper by considering the following:
- Future Outlook: What are well-informed industry analysts predicting for ACHV’s future growth? Take a look at our free research report of analyst consensus for ACHV’s outlook.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.
About NasdaqCM:ACHV
Achieve Life Sciences
A clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction.
High growth potential with mediocre balance sheet.
Market Insights
Community Narratives
